Cargando…

Evaluation of antibody kinetics and durability in healthy individuals vaccinated with inactivated COVID-19 vaccine (CoronaVac): A cross-sectional and cohort study in Zhejiang, China

BACKGROUND: Although inactivated COVID-19 vaccines are proven to be safe and effective in the general population, the dynamic response and duration of antibodies after vaccination in the real world should be further assessed. METHODS: We enrolled 1067 volunteers who had been vaccinated with one or t...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Hangjie, Hua, Qianhui, Nani Xu, Nani, Zhang, Xinpei, Chen, Bo, Ma, Xijun, Hu, Jie, Chen, Zhongbing, Yu, Pengfei, Lei, Huijun, Wang, Shenyu, Ding, Linling, Fu, Jian, Liao, Yuting, Yang, Juan, Jiang, Jianmin, Lv, Huakun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: eLife Sciences Publications, Ltd 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10110235/
https://www.ncbi.nlm.nih.gov/pubmed/36928099
http://dx.doi.org/10.7554/eLife.84056
_version_ 1785027228106489856
author Zhang, Hangjie
Hua, Qianhui
Nani Xu, Nani
Zhang, Xinpei
Chen, Bo
Ma, Xijun
Hu, Jie
Chen, Zhongbing
Yu, Pengfei
Lei, Huijun
Wang, Shenyu
Ding, Linling
Fu, Jian
Liao, Yuting
Yang, Juan
Jiang, Jianmin
Lv, Huakun
author_facet Zhang, Hangjie
Hua, Qianhui
Nani Xu, Nani
Zhang, Xinpei
Chen, Bo
Ma, Xijun
Hu, Jie
Chen, Zhongbing
Yu, Pengfei
Lei, Huijun
Wang, Shenyu
Ding, Linling
Fu, Jian
Liao, Yuting
Yang, Juan
Jiang, Jianmin
Lv, Huakun
author_sort Zhang, Hangjie
collection PubMed
description BACKGROUND: Although inactivated COVID-19 vaccines are proven to be safe and effective in the general population, the dynamic response and duration of antibodies after vaccination in the real world should be further assessed. METHODS: We enrolled 1067 volunteers who had been vaccinated with one or two doses of CoronaVac in Zhejiang Province, China. Another 90 healthy adults without previous vaccinations were recruited and vaccinated with three doses of CoronaVac, 28 days and 6 months apart. Serum samples were collected from multiple timepoints and analyzed for specific IgM/IgG and neutralizing antibodies (NAbs) for immunogenicity evaluation. Antibody responses to the Delta and Omicron variants were measured by pseudovirus-based neutralization tests. RESULTS: Our results revealed that binding antibody IgM peaked 14–28 days after one dose of CoronaVac, while IgG and NAbs peaked approximately 1 month after the second dose then declined slightly over time. Antibody responses had waned by month 6 after vaccination and became undetectable in the majority of individuals at 12 months. Levels of NAbs to live SARS-CoV-2 were correlated with anti-SARS-CoV-2 IgG and NAbs to pseudovirus, but not IgM. Homologous booster around 6 months after primary vaccination activated anamnestic immunity and raised NAbs 25.5-fold. The neutralized fraction subsequently rose to 36.0% for Delta (p=0.03) and 4.3% for Omicron (p=0.004), and the response rate for Omicron rose from 7.9% (7/89)–17.8% (16/90). CONCLUSIONS: Two doses of CoronaVac vaccine resulted in limited protection over a short duration. The inactivated vaccine booster can reverse the decrease of antibody levels to prime strain, but it does not elicit potent neutralization against Omicron; therefore, the optimization of booster procedures is vital. FUNDING: Key Research and Development Program of Zhejiang Province; Key Program of Health Commission of Zhejiang Province/ Science Foundation of National Health Commission; Major Program of Zhejiang Municipal Natural Science Foundation; Explorer Program of Zhejiang Municipal Natural Science Foundation.
format Online
Article
Text
id pubmed-10110235
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher eLife Sciences Publications, Ltd
record_format MEDLINE/PubMed
spelling pubmed-101102352023-04-18 Evaluation of antibody kinetics and durability in healthy individuals vaccinated with inactivated COVID-19 vaccine (CoronaVac): A cross-sectional and cohort study in Zhejiang, China Zhang, Hangjie Hua, Qianhui Nani Xu, Nani Zhang, Xinpei Chen, Bo Ma, Xijun Hu, Jie Chen, Zhongbing Yu, Pengfei Lei, Huijun Wang, Shenyu Ding, Linling Fu, Jian Liao, Yuting Yang, Juan Jiang, Jianmin Lv, Huakun eLife Epidemiology and Global Health BACKGROUND: Although inactivated COVID-19 vaccines are proven to be safe and effective in the general population, the dynamic response and duration of antibodies after vaccination in the real world should be further assessed. METHODS: We enrolled 1067 volunteers who had been vaccinated with one or two doses of CoronaVac in Zhejiang Province, China. Another 90 healthy adults without previous vaccinations were recruited and vaccinated with three doses of CoronaVac, 28 days and 6 months apart. Serum samples were collected from multiple timepoints and analyzed for specific IgM/IgG and neutralizing antibodies (NAbs) for immunogenicity evaluation. Antibody responses to the Delta and Omicron variants were measured by pseudovirus-based neutralization tests. RESULTS: Our results revealed that binding antibody IgM peaked 14–28 days after one dose of CoronaVac, while IgG and NAbs peaked approximately 1 month after the second dose then declined slightly over time. Antibody responses had waned by month 6 after vaccination and became undetectable in the majority of individuals at 12 months. Levels of NAbs to live SARS-CoV-2 were correlated with anti-SARS-CoV-2 IgG and NAbs to pseudovirus, but not IgM. Homologous booster around 6 months after primary vaccination activated anamnestic immunity and raised NAbs 25.5-fold. The neutralized fraction subsequently rose to 36.0% for Delta (p=0.03) and 4.3% for Omicron (p=0.004), and the response rate for Omicron rose from 7.9% (7/89)–17.8% (16/90). CONCLUSIONS: Two doses of CoronaVac vaccine resulted in limited protection over a short duration. The inactivated vaccine booster can reverse the decrease of antibody levels to prime strain, but it does not elicit potent neutralization against Omicron; therefore, the optimization of booster procedures is vital. FUNDING: Key Research and Development Program of Zhejiang Province; Key Program of Health Commission of Zhejiang Province/ Science Foundation of National Health Commission; Major Program of Zhejiang Municipal Natural Science Foundation; Explorer Program of Zhejiang Municipal Natural Science Foundation. eLife Sciences Publications, Ltd 2023-03-16 /pmc/articles/PMC10110235/ /pubmed/36928099 http://dx.doi.org/10.7554/eLife.84056 Text en © 2023, Zhang, Hua et al https://creativecommons.org/licenses/by/4.0/This article is distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use and redistribution provided that the original author and source are credited.
spellingShingle Epidemiology and Global Health
Zhang, Hangjie
Hua, Qianhui
Nani Xu, Nani
Zhang, Xinpei
Chen, Bo
Ma, Xijun
Hu, Jie
Chen, Zhongbing
Yu, Pengfei
Lei, Huijun
Wang, Shenyu
Ding, Linling
Fu, Jian
Liao, Yuting
Yang, Juan
Jiang, Jianmin
Lv, Huakun
Evaluation of antibody kinetics and durability in healthy individuals vaccinated with inactivated COVID-19 vaccine (CoronaVac): A cross-sectional and cohort study in Zhejiang, China
title Evaluation of antibody kinetics and durability in healthy individuals vaccinated with inactivated COVID-19 vaccine (CoronaVac): A cross-sectional and cohort study in Zhejiang, China
title_full Evaluation of antibody kinetics and durability in healthy individuals vaccinated with inactivated COVID-19 vaccine (CoronaVac): A cross-sectional and cohort study in Zhejiang, China
title_fullStr Evaluation of antibody kinetics and durability in healthy individuals vaccinated with inactivated COVID-19 vaccine (CoronaVac): A cross-sectional and cohort study in Zhejiang, China
title_full_unstemmed Evaluation of antibody kinetics and durability in healthy individuals vaccinated with inactivated COVID-19 vaccine (CoronaVac): A cross-sectional and cohort study in Zhejiang, China
title_short Evaluation of antibody kinetics and durability in healthy individuals vaccinated with inactivated COVID-19 vaccine (CoronaVac): A cross-sectional and cohort study in Zhejiang, China
title_sort evaluation of antibody kinetics and durability in healthy individuals vaccinated with inactivated covid-19 vaccine (coronavac): a cross-sectional and cohort study in zhejiang, china
topic Epidemiology and Global Health
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10110235/
https://www.ncbi.nlm.nih.gov/pubmed/36928099
http://dx.doi.org/10.7554/eLife.84056
work_keys_str_mv AT zhanghangjie evaluationofantibodykineticsanddurabilityinhealthyindividualsvaccinatedwithinactivatedcovid19vaccinecoronavacacrosssectionalandcohortstudyinzhejiangchina
AT huaqianhui evaluationofantibodykineticsanddurabilityinhealthyindividualsvaccinatedwithinactivatedcovid19vaccinecoronavacacrosssectionalandcohortstudyinzhejiangchina
AT nanixunani evaluationofantibodykineticsanddurabilityinhealthyindividualsvaccinatedwithinactivatedcovid19vaccinecoronavacacrosssectionalandcohortstudyinzhejiangchina
AT zhangxinpei evaluationofantibodykineticsanddurabilityinhealthyindividualsvaccinatedwithinactivatedcovid19vaccinecoronavacacrosssectionalandcohortstudyinzhejiangchina
AT chenbo evaluationofantibodykineticsanddurabilityinhealthyindividualsvaccinatedwithinactivatedcovid19vaccinecoronavacacrosssectionalandcohortstudyinzhejiangchina
AT maxijun evaluationofantibodykineticsanddurabilityinhealthyindividualsvaccinatedwithinactivatedcovid19vaccinecoronavacacrosssectionalandcohortstudyinzhejiangchina
AT hujie evaluationofantibodykineticsanddurabilityinhealthyindividualsvaccinatedwithinactivatedcovid19vaccinecoronavacacrosssectionalandcohortstudyinzhejiangchina
AT chenzhongbing evaluationofantibodykineticsanddurabilityinhealthyindividualsvaccinatedwithinactivatedcovid19vaccinecoronavacacrosssectionalandcohortstudyinzhejiangchina
AT yupengfei evaluationofantibodykineticsanddurabilityinhealthyindividualsvaccinatedwithinactivatedcovid19vaccinecoronavacacrosssectionalandcohortstudyinzhejiangchina
AT leihuijun evaluationofantibodykineticsanddurabilityinhealthyindividualsvaccinatedwithinactivatedcovid19vaccinecoronavacacrosssectionalandcohortstudyinzhejiangchina
AT wangshenyu evaluationofantibodykineticsanddurabilityinhealthyindividualsvaccinatedwithinactivatedcovid19vaccinecoronavacacrosssectionalandcohortstudyinzhejiangchina
AT dinglinling evaluationofantibodykineticsanddurabilityinhealthyindividualsvaccinatedwithinactivatedcovid19vaccinecoronavacacrosssectionalandcohortstudyinzhejiangchina
AT fujian evaluationofantibodykineticsanddurabilityinhealthyindividualsvaccinatedwithinactivatedcovid19vaccinecoronavacacrosssectionalandcohortstudyinzhejiangchina
AT liaoyuting evaluationofantibodykineticsanddurabilityinhealthyindividualsvaccinatedwithinactivatedcovid19vaccinecoronavacacrosssectionalandcohortstudyinzhejiangchina
AT yangjuan evaluationofantibodykineticsanddurabilityinhealthyindividualsvaccinatedwithinactivatedcovid19vaccinecoronavacacrosssectionalandcohortstudyinzhejiangchina
AT jiangjianmin evaluationofantibodykineticsanddurabilityinhealthyindividualsvaccinatedwithinactivatedcovid19vaccinecoronavacacrosssectionalandcohortstudyinzhejiangchina
AT lvhuakun evaluationofantibodykineticsanddurabilityinhealthyindividualsvaccinatedwithinactivatedcovid19vaccinecoronavacacrosssectionalandcohortstudyinzhejiangchina